210 related articles for article (PubMed ID: 22380928)
1. Prostacyclin receptor in tumor endothelial cells promotes angiogenesis in an autocrine manner.
Osawa T; Ohga N; Hida Y; Kitayama K; Akiyama K; Onodera Y; Fujie M; Shinohara N; Shindoh M; Nonomura K; Hida K
Cancer Sci; 2012 Jun; 103(6):1038-44. PubMed ID: 22380928
[TBL] [Abstract][Full Text] [Related]
2. Interaction of the human prostacyclin receptor with the PDZ adapter protein PDZK1: role in endothelial cell migration and angiogenesis.
Turner EC; Mulvaney EP; Reid HM; Kinsella BT
Mol Biol Cell; 2011 Aug; 22(15):2664-79. PubMed ID: 21653824
[TBL] [Abstract][Full Text] [Related]
3. Prostanoids regulate angiogenesis acting primarily on IP and EP4 receptors.
Hoang KG; Allison S; Murray M; Petrovic N
Microvasc Res; 2015 Sep; 101():127-34. PubMed ID: 26188701
[TBL] [Abstract][Full Text] [Related]
4. Suprabasin as a novel tumor endothelial cell marker.
Alam MT; Nagao-Kitamoto H; Ohga N; Akiyama K; Maishi N; Kawamoto T; Shinohara N; Taketomi A; Shindoh M; Hida Y; Hida K
Cancer Sci; 2014 Dec; 105(12):1533-40. PubMed ID: 25283635
[TBL] [Abstract][Full Text] [Related]
5. 4,5-Dihydro-1H-imidazol-2-yl)-[4-(4-isopropoxy-benzyl)-phenyl]-amine (RO1138452) is a selective, pseudo-irreversible orthosteric antagonist at the prostacyclin (IP)-receptor expressed by human airway epithelial cells: IP-receptor-mediated inhibition of CXCL9 and CXCL10 release.
Ayer LM; Wilson SM; Traves SL; Proud D; Giembycz MA
J Pharmacol Exp Ther; 2008 Feb; 324(2):815-26. PubMed ID: 17962517
[TBL] [Abstract][Full Text] [Related]
6. Investigation of the prostacyclin (IP) receptor antagonist RO1138452 on isolated blood vessel and platelet preparations.
Jones RL; Wise H; Clark R; Whiting RL; Bley KR
Br J Pharmacol; 2006 Sep; 149(1):110-20. PubMed ID: 16880763
[TBL] [Abstract][Full Text] [Related]
7. Biglycan is a specific marker and an autocrine angiogenic factor of tumour endothelial cells.
Yamamoto K; Ohga N; Hida Y; Maishi N; Kawamoto T; Kitayama K; Akiyama K; Osawa T; Kondoh M; Matsuda K; Onodera Y; Fujie M; Kaga K; Hirano S; Shinohara N; Shindoh M; Hida K
Br J Cancer; 2012 Mar; 106(6):1214-23. PubMed ID: 22374465
[TBL] [Abstract][Full Text] [Related]
8. RO1138452 and RO3244794: characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists.
Bley KR; Bhattacharya A; Daniels DV; Gever J; Jahangir A; O'Yang C; Smith S; Srinivasan D; Ford AP; Jett MF
Br J Pharmacol; 2006 Feb; 147(3):335-45. PubMed ID: 16331286
[TBL] [Abstract][Full Text] [Related]
9. CXCR7: a novel tumor endothelial marker in renal cell carcinoma.
Maishi N; Ohga N; Hida Y; Akiyama K; Kitayama K; Osawa T; Onodera Y; Shinohara N; Nonomura K; Shindoh M; Hida K
Pathol Int; 2012 May; 62(5):309-17. PubMed ID: 22524658
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel targets for antiangiogenic therapy by comparing the gene expressions of tumor and normal endothelial cells.
Otsubo T; Hida Y; Ohga N; Sato H; Kai T; Matsuki Y; Takasu H; Akiyama K; Maishi N; Kawamoto T; Shinohara N; Nonomura K; Hida K
Cancer Sci; 2014 May; 105(5):560-7. PubMed ID: 24602018
[TBL] [Abstract][Full Text] [Related]
11. Altered angiogenesis in the tumor microenvironment.
Hida K; Kawamoto T; Ohga N; Akiyama K; Hida Y; Shindoh M
Pathol Int; 2011 Nov; 61(11):630-7. PubMed ID: 22029673
[TBL] [Abstract][Full Text] [Related]
12. CXCL12-CXCR7 axis is important for tumor endothelial cell angiogenic property.
Yamada K; Maishi N; Akiyama K; Towfik Alam M; Ohga N; Kawamoto T; Shindoh M; Takahashi N; Kamiyama T; Hida Y; Taketomi A; Hida K
Int J Cancer; 2015 Dec; 137(12):2825-36. PubMed ID: 26100110
[TBL] [Abstract][Full Text] [Related]
13. Tumor endothelial cells with high aldehyde dehydrogenase activity show drug resistance.
Hida K; Maishi N; Akiyama K; Ohmura-Kakutani H; Torii C; Ohga N; Osawa T; Kikuchi H; Morimoto H; Morimoto M; Shindoh M; Shinohara N; Hida Y
Cancer Sci; 2017 Nov; 108(11):2195-2203. PubMed ID: 28851003
[TBL] [Abstract][Full Text] [Related]
14. The F-prostaglandin receptor is a novel marker for tumor endothelial cells in renal cell carcinoma.
Akiyama K; Ohga N; Maishi N; Hida Y; Kitayama K; Kawamoto T; Osawa T; Suzuki Y; Shinohara N; Nonomura K; Shindoh M; Hida K
Pathol Int; 2013 Jan; 63(1):37-44. PubMed ID: 23356224
[TBL] [Abstract][Full Text] [Related]
15. Suppression of renal cell carcinoma growth in vivo by forced expression of vascular endothelial growth inhibitor.
Zhang N; Wu P; Shayiremu D; Wu L; Shan H; Ye L; Zhao X; Cai J; Jiang WG; Gong K; Yang Y
Int J Oncol; 2013 May; 42(5):1664-73. PubMed ID: 23545578
[TBL] [Abstract][Full Text] [Related]
16. Adrenomedullin antagonist suppresses tumor formation in renal cell carcinoma through inhibitory effects on tumor endothelial cells and endothelial progenitor mobilization.
Tsuchiya K; Hida K; Hida Y; Muraki C; Ohga N; Akino T; Kondo T; Miseki T; Nakagawa K; Shindoh M; Harabayashi T; Shinohara N; Nonomura K; Kobayashi M
Int J Oncol; 2010 Jun; 36(6):1379-86. PubMed ID: 20428760
[TBL] [Abstract][Full Text] [Related]
17. Differential actions of the prostacyclin analogues treprostinil and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins.
Orie NN; Ledwozyw A; Williams DJ; Whittle BJ; Clapp LH
Prostaglandins Other Lipid Mediat; 2013 Oct; 106():1-7. PubMed ID: 23872196
[TBL] [Abstract][Full Text] [Related]
18. Altered angiogenesis and survival in human tumor-derived endothelial cells.
Bussolati B; Deambrosis I; Russo S; Deregibus MC; Camussi G
FASEB J; 2003 Jun; 17(9):1159-61. PubMed ID: 12709414
[TBL] [Abstract][Full Text] [Related]
19. Pharmacological and expression profile of the prostaglandin I(2) receptor in the rat craniovascular system.
Myren M; Olesen J; Gupta S
Vascul Pharmacol; 2011; 55(1-3):50-8. PubMed ID: 21749934
[TBL] [Abstract][Full Text] [Related]
20. Protective Role of mPGES-1 (Microsomal Prostaglandin E Synthase-1)-Derived PGE
Hao H; Hu S; Wan Q; Xu C; Chen H; Zhu L; Xu Z; Meng J; Breyer RM; Li N; Liu DP; FitzGerald GA; Wang M
Arterioscler Thromb Vasc Biol; 2018 May; 38(5):1115-1124. PubMed ID: 29599139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
